Background: Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became controversial in the early 1980's after reports ...

Why Don't Patients Take Their Phosphate Binders? Online survey findings showed significant challenges with compliance to phosphate binder therapy. Among 200 dialysis patients, 37% were non ...

BOSTON — Patients on kidney dialysis reported better adherence ... and 126 answered questions about barriers to phosphate binder adherence. Forgetting to take the medication was listed as ...

The worldwide hyperphosphatemia industry is anticipated to reach a valuation of around USD 12.66 billion in 2023 and grow at a compound annual growth rate (CAGR) of more than 4.8% until 2033. By 2033, ...

When people think of kidney disease, they usually think about problems with how the body removes waste—not about skin issues. But for many people living with kidney disease, itchy skin and rashes are ...

In a survey commissioned by Unicycive that was conducted in 2022, kidney disease specialists said that the greatest unmet need in the treatment of hyperphosphataemia with phosphate binders is a ...

"[The] vote by the CRDAC is a promising development for the chronic kidney disease community ... which are all limited to the phosphate binder class," said Mike Raab, Ardelyx' president and ...

on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers a different mechanism ...